Merck KGaA (FRA:MRK) received a €95.00 ($113.10) target price from analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Thursday. The brokerage presently has a “neutral” rating on the healthcare company’s stock. JPMorgan Chase & Co.’s price target would indicate a potential upside of 1.58% from the company’s previous close.
MRK has been the subject of several other research reports. Independent Research set a €105.00 ($125.00) price target on Merck KGaA and gave the stock a “neutral” rating in a research note on Wednesday, September 6th. Kepler Capital Markets set a €115.00 ($136.90) price target on Merck KGaA and gave the stock a “buy” rating in a research note on Wednesday, October 4th. Berenberg Bank set a €116.00 ($138.10) price target on Merck KGaA and gave the stock a “buy” rating in a research note on Tuesday, September 19th. Sanford C. Bernstein set a €115.00 ($136.90) price target on Merck KGaA and gave the stock a “buy” rating in a research note on Wednesday, November 29th. Finally, UBS Group set a €120.00 ($142.86) price target on Merck KGaA and gave the stock a “buy” rating in a research note on Thursday, November 9th. Twelve analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of €107.57 ($128.06).
Merck KGaA (MRK) opened at €93.52 ($111.33) on Thursday. The firm has a market capitalization of $12,020.00 and a price-to-earnings ratio of 21.90. Merck KGaA has a 12 month low of €87.33 ($103.96) and a 12 month high of €115.00 ($136.90).
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/01/06/merck-kgaa-mrk-pt-set-at-95-00-by-jpmorgan-chase-co.html.
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.